More than 60 organizations, including NVHR, signed onto a letter urging the Trump administration to invest in the Department of Health & Human Services Viral Hepatitis Action Plan and to commit in words and action to the elimination of HBV and HCV in the United States by 2030. You may download a copy of the letter here.
Last Updated on May 13, 2020 by HepFree NYC
A letter from the Hepatitis Appropriations Partnership urges Congress to appropriate $62.8 million for the Division of Viral Hepatitis
The AIDS Budget and Appropriations Coalition (ABAC), in collaboration with the Hepatitis Appropriations Partnership (HAP) and other coalitions, has developed an organizational sign-on letter urging the president to adequately fund hepatitis and HIV programs.
President Obama has proposed to double funding for DVH (for a total of $62.8 million).
Intern will work under the supervision of the Director of Program Implementation & Capacity Building in the NYC Department of Health, Viral Hepatitis Surveillance, Prevention & Control Program.
The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
May Hepatitis Awareness Month, National Hepatitis Testing Day and Hispanic Hepatitis Awareness Day.
DA approved revisions to the Olysio (simeprevir) label to include dosing recommendations for the treatment of HCV/HIV-1 coinfection and to expand the indications and usage to include genotype 4 infection.
This report presents an overview of the NYC Health Department’s 2018 surveillance and research data on hepatitis B and C in NYC, as well as the Health Department’s programmatic activities to address these epidemics.
